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Abstract
Background: Treatment with tenofovir is sometimes associated with renal dysfunction. Limited information is available on
this side effect in patients with small body weight, although the use of tenofovir will spread rapidly in Asia and Africa, where
patients are likely to be of smaller body weight.
Methods: In a single-center cohort, Japanese patients with HIV infection who started tenofovir-containing antiretroviral
therapy were retrospectively analyzed. The incidence of tenofovir-associated renal dysfunction, defined as more than 25%
decrement of estimated glomerular filtration rate (eGFR) from the baseline, was determined. The effects of small body
weight and body mass index (BMI) on tenofovir-associated renal dysfunction, respectively, were estimated in univariate and
multivariate Cox hazards models as the primary exposure. Other possible risk factors were evaluated by univariate analysis
and those found significant were entered into the multivariate analysis.
Results: The median weight of 495 patients was 63 kg. Tenofovir-related renal dysfunction occurred in 97 (19.6%) patients
(incidence: 10.5 per 100 person-years). Univariate analysis showed that the incidence of tenofovir-related renal dysfunction
was significantly associated with smaller body weight and BMI, respectively (per 5 kg decrement, HR=1.23; 95% CI, 1.10–
1.37; p,0.001)(per 1 kg/m
2 decrement, HR=1.14; 95% CI, 1.05–1.23; p=0.001). Old age, high baseline eGFR, low serum
creatinine, low CD4 count, high HIV viral load, concurrent nephrotoxic drugs, hepatitis C infection, and current smoking
were also associated with tenofovir-related renal dysfunction. Multivariate analysis identified small body weight as a
significant risk (adjusted HR=1.13; 95% CI, 1.01–1.27; p=0.039), while small BMI had marginal significance (adjusted
HR=1.07; 95% CI 1.00–1.16; p=0.058).
Conclusion: The incidence of tenofovir-associated renal dysfunction in Japanese patients was high. Small body weight was
identified as an independent risk factor for tenofovir-associated renal dysfunction. Close monitoring of renal function is
advocated for patients with small body weight treated with tenofovir.
Citation: Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, et al. (2011) Impact of Small Body Weight on Tenofovir-Associated Renal Dysfunction in HIV-
Infected Patients: A Retrospective Cohort Study of Japanese Patients. PLoS ONE 6(7): e22661. doi:10.1371/journal.pone.0022661
Editor: Gary Maartens, University of Cape Town, South Africa
Received February 24, 2011; Accepted June 28, 2011; Published July 25, 2011
Copyright:  2011 Nishijima et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a Grant-in-Aid for AIDS Research from the Ministry of Health, Labor, and Welfare of Japan (H20-AIDS-002). The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: tnishiji@acc.ncgm.go.jp
Introduction
Tenofovir disoproxil fumarate (TDF) is one of the most widely
used nucleotide reverse transcriptase inhibitors (NRTI) for patients
with HIV infection, with proven efficacy and safety [1–6].
However, TDF is known to cause renal proximal tubular
dysfunction, and several case reports have been published with
TDF-related Fanconi syndrome, diabetes insipidus, and acute
tubular necrosis, which sometimes lead to acute renal failure [7–
10]. Long-term TDF use also reduces glomerular filtration rate
more than other NRTIs [11–14]. To date, the nephrotoxic effect
of TDF is regarded as mild and tolerable. A recently published
meta-analysis has reported that the use of TDF is associated with a
statistically significant but only modest renal dysfunction, and
recommended that TDF use should not be restricted even when
regular monitoring of renal function and serum phosphate levels is
impractical [15]. However, the TDF-related renal dysfunction has
hardly been evaluated in patients with small body weight, who are
potentially at higher risk for larger drug exposure and thus, more
severe toxicity [16–19].
The 2010 WHO guideline on antiretroviral therapy for HIV
infection in adults and adolescents, usually applied to resource-
constrained settings, recommends TDF as one of the components
of first line therapies (URL:http://whqlibdoc.who.int/publications/
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e226612010/9789241599764_eng.pdf). It is expected that the use of TDF
will spread rapidly in Asia and Africa in the near future, where
patients are more likely to be of small body weight. Thus, at this
stage, it is important to establish the relationship between TDF-
associated renal dysfunction and body weight. A small body weight
is considered a risk factor for TDF-associated renal dysfunction, in
addition to old age, high baseline serum creatinine level, low CD4
count, concurrent use of ritonavir-boosted protease inhibitor, and
concurrent use of nephrotoxic drugs [4,17,19–21]. To our
knowledge, there is almost no report that primarily analyzed the
influence of body weight on TDF-associated renal dysfunction.
Since Japanese are generally of smaller stature and have a lower
median body weight than Whites and African Americans, who
mostly comprise the cohorts of studies published to date, it is
important to investigate the impact of TDF-associated renal
dysfunction in Japanese patients.
Based on the above background, the present study was designed
to determine the incidence of TDF-associated renal dysfunction in
Japanese patients and analyze the impact of small body weight on
TDF-associated renal dysfunction.
Methods
Ethics Statement
This study was approved by the Human Research Ethics
Committee of National Center for Global Health and Medicine
(Text S1). All patients included in this study provided a written
informed consent for their clinical and laboratory data to be used
and be published for research purposes. This study has been
conducted according to the principles expressed in the Declaration
of Helsinki.
Study Design and Settings
We performed a single-center, retrospective cohort study of
HIV-infected Japanese patients using medical records at the
National Center for Global Health and Medicine, Tokyo, Japan.
Our facility is one of the largest clinics for patients with HIV
infection in Japan with more than 2,700 registered patients.
Study Subjects
The study population were patients .17 years of age who
commenced treatment with standard 300 mg/day of TDF-
containing antiretroviral regimen at our clinic between January
1, 2002 to March 31, 2009. Both treatment-naive and patients
with experience in antiretroviral treatment but not TDF, with an
estimated glomerular filtration rate (eGFR) of .60 ml/min/
1.73 m
2 were enrolled. Patients were followed up until September
31, 2009. Patients were excluded if their follow-up period at our
facility was less than 24 weeks after commencement of TDF-based
therapy, if they had started TDF at other facilities, or if there was
evidence of prior TDF use. We only included Japanese patients in
order to examine a population with comparatively homogenous
basic demographics and background.
Measurements
Outcomemeasure:TDF-associatedrenaldysfunction. We
defined TDF-associated renal dysfunction as more than 25%
decrease in eGFR relative to the baseline [17,22,23]. Baseline
eGFR was estimated for each patient from the average of two
successive serum creatinine measurements made closest to and
preceding the commencement of TDF by no more than 90 days.
Changes in eGFR were plotted from the baseline measurement until
the value diminished to less than 75% of the baseline or at the end of
the follow-up period. The eGFR values at occurrence of TDF-
associated renal dysfunction, at censoring, and closest to and
preceding 24, 48, and 96 weeks to the diagnosis were collected.
Patients generally visited our clinic between every month to every 3
months, and measurement of eGFR was usually conducted on every
visit. eGFR was calculated using the equation from the 4-variable
Modification of Diet in Renal Disease (MDRD) study [24].
Primary exposure variable. Our primary exposure
variables were body weight and body mass index (BMI) at the
time of commencement of TDF-containing antiretroviral therapy
(ART). BMI was calculated by the equation: BMI=[body weight
(kg)/height (m)
2].
Other variables: potential risk factors. Potential risk
factors for TDF-associated renal dysfunction were determined
according to previous studies and collected together with the basic
demographics from the medical charts [4,19,20,25]. They
included sex, age, baseline laboratory data: CD4 cell count,
HIV viral load, and serum creatinine, and other medical
conditions (antiretroviral treatment-naı ¨ve or experienced,
concurrent ritonavir-boosted protease inhibitors, concurrent
nephrotoxic drugs such as ganciclovir, sulfamethoxazole/
trimethoprim, ciprofloxacin, and NSAIDs, diabetes mellitus, co-
infection with hepatitis B defined by positive hepatitis B surface
antigen, co-infection with hepatitis C defined by positive HCV
viral load, hypertension defined by current treatment with
antihypertensive agents, dyslipidemia defined by current
treatment with lipid-lowering agents, and current smoking) [26].
We used the data on or closest to and preceding the day of starting
TDF-containing ART by no more than 90 days. The data on
weight change from the baseline to the end of follow-up period
and the frequency of eGFR monitoring for each patient were
collected.
Statistical analysis
The time to 25% decline in eGFR from the baseline was
calculated from the date of treatment initiation to the date of
occurrence of TDF-associated renal dysfunction. Censored cases
represented those who discontinued TDF, dropped out, referred to
other facilities, or at the end of follow-up period. The time from
TDF initiation to 25% decrease in eGFR was analyzed by the
Kaplan Meier method for the whole cohort. To estimate the
impact of body weight on the incidence of TDF-associated renal
dysfunction, we calculated the impact of every 5 kg decrement
from the median weight using Cox proportional hazards
regression analysis. The impact of every 1 kg/m
2 decrement in
BMI on the incidence of TDF-associated renal dysfunction was
estimated by the same method. The impact of each basic
demographics, baseline laboratory data, and other medical
conditions listed above was also estimated with univariate Cox
proportional hazards regression.
To estimate the unbiased prognostic impact of weight on TDF-
associated renal dysfunction, we conducted three models using
multivariate Cox proportional hazards regression analysis. Model
1 was the aforementioned univariate analysis for every 5 kg
decrement. Model 2 included sex, age plus model 1 in order to
adjust for basic characteristics. In model 3, we added variables
with P values,0.05 in univariate analysis for adjustment (these
included age per 10 years, serum creatinine .0.8 mg/dl, CD4
count ,200/ml, HIV viral load per log10/ml, concurrent
nephrotoxic drugs, co-infection with hepatitis C, and current
smoking). Concurrent ritonavir-boosted protease inhibitors were
also added in Model 3 although their p value was 0.116 in the
univariate analysis. This was based on the results of several studies
suggesting that concurrent use of ritonavir-boosted protease
inhibitors is a risk factor for TDF-associated renal dysfunction
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because of its multicollinearity with sex, age, and serum creatinine,
since eGFR was gained by the equation of those variables. The
impact of every 1 kg/m
2 decrement in BMI on the incidence of
TDF-associated renal dysfunction was estimated by the same
method with Model 1 to Model 3.
Four other analyses were conducted to further examine the
relationship between low body weight and TDF-associated renal
dysfunction. First, the time from initiation of TDF therapy to
25% decrease in eGFR was analyzed by the Kaplan Meier
method for intertertile baseline body weight categories: ,59,
59–67, and .67 kg. The log-rank test was used to determine
statistical significance. Second, to investigate the impact of
changes in muscle mass on changes in the eGFR as calculated
by MDRD, we compared weight changes with one-way
ANOVA among intertertile baseline weight categories. We also
conducted the sensitivity analysis by adding the variable ‘‘weight
change’’ in multivariate analysis. Third, the median and
interquartile value for the actual fall in eGFR from the baseline
to 24, 48, and 96 weeks for the whole cohort and three baseline
weight categories, respectively, were calculated. The eGFR
value at 24, 48, and 96 weeks included those that were censored
before reaching 24, 48, and 96 weeks, respectively, so that we
could interpret the data for actual fall in eGFR, including not
only survived cases but also censored cases. Fourth, we counted
the number of patients whose eGFR decreased to ,60 and
,10 ml/min/1.73 m
2, and who discontinued TDF with the
clinical diagnosis of renal dysfunction due to TDF. Chi-square
test was used to determine whether the difference among the
weight categories was statistically significant.
Statistical significance was d e f i n e da tt w o - s i d e dpv a l u e s ,
0.05. We used hazard ratios (HRs) and 95% confidence intervals
(CIs) to estimate the impact of each variable on TDF-associated
renal dysfunction. All statistical analyses were performed with
The Statistical Package for Social Sciences ver. 17.0 (SPSS,
Chicago, IL).
Results
Between January 1, 2002 to March 31, 2009, 599 patients
started TDF-containing ART (Figure 1). Of these, 104 patients
were excluded based on the abovementioned criteria. Thus 495
patients were included in the present study (Dataset S1). Table 1
shows the demographics, laboratory data, and medical conditions
of the study population at baseline. Two patients received ART
with 3 NRTIs, 3 patients received ART with one protease
inhibitor (PI), one non-NRTI (NNRTI), and tenofovir/emtricita-
bine, and the remaining patients had a standard ART with 2
NRTIs and either PI, NNRTI, or integrase inhibitor (INI). The
median body weight and BMI were 63 kg and 21.9 kg/m
2,
respectively. The median age of the patients was 38 years and
95.2% were males. The eGFR was well maintained (median:
120.9 ml/min/1.73 m
2), and the median baseline CD4 count was
247/ml. Of the total, 208 patients (42%) were antiretroviral
treatment naı ¨ve, while 287 were treatment-experienced patients.
Viral load was suppressed to ,50 copies/ml in 162 (32.7%)
patients. 403 (81.4%) were on concurrent PIs as the key drug, 367
(74.1%) were on ritonavir-boosted PIs, and only 83 (16.8%) had
NNRTIs as the key drug. Smoking was prevalent among the study
population, as 240 (48.5%) were identified as a current smoker.
TDF-associated renal dysfunction defined by more than 25%
decrease of eGFR from baseline occurred in 97 patients (19.6%),
with an estimated incidence of 10.5 per 100 person-years. The
median time from commencement of TDF to occurrence of TDF-
associated renal dysfunction was 39 weeks (IQR 13.5–99.4 weeks)
(range: 1–1,841 days). The total observation period was 924.7
patient-years (median 72 weeks, IQR 38.6–139.3 weeks). Figure 2
shows the Kaplan-Meier survival curve for the occurrence of
TDF-associated renal dysfunction for the whole cohort.
Univariate analysis showed a significant relationship between
TDF-associated renal dysfunction and every 5 kg less than the
median body weight (HR=1.23; 95% CI, 1.10–1.37; p,0.001),
and 1 kg/m
2 less BMI than the median BMI (HR=1.14; 95% CI,
1.05–1.23; p=0.001) (Table 2). Furthermore, old age, high eGFR,
low serum creatinine, low CD4 counts, high HIV viral load,
concurrent use of nephrotoxic drugs, presence of chronic hepatitis
C, and smoking were associated with TDF-related renal
dysfunction. On the other hand, concurrent use of PIs, ritonavir
boosted PIs, and LPV/r tended to be associated with TDF-related
renal dysfunction, albeit statistically insignificant. Treatment-naı ¨ve
or Treatment-experienced was not associated with TDF-related
renal dysfunction.
Multivariate analysis showed that every 5 kg less than the
median body weight was a significant risk for TDF-associated
renal dysfunction after adjustment for sex and age (adjusted
HR=1.21; 95% CI, 1.07–1.36; p=0.002) (Table 3, Model 2), and
also after adjustment for other risk factors (adjusted HR=1.13;
95% CI, 1.01–1.27; p=0.039) (Table 3, Model 3). Similarly, every
1 kg/m
2 less than the median BMI was also a significant risk factor
for TDF-associated renal dysfunction even after adjustment for sex
and age (adjusted HR=1.13; 95% CI 1.05–1.22; p=0.002)
(Table 4, Model 2), and tended to be a significant factor after
adjustment for other variables (adjusted HR=1.07; 95% CI 1.00–
1.16; p=0.058) (Table 4, Model 3). Old age and current smoking
were also independent risk factors in both multivariate analysis for
body weight and BMI (Table 3, Model 3 and Table 4, Model 3).
In complementary analyses, First, Figure 3 shows the relation
between probability of TDF-associated nephrotoxicity and time
from initiation of TDF therapy to 25% decrease in eGFR analyzed
by the Kaplan Meier method for intertertile baseline weight
categories. Compared to patients with baseline body weight
.67 kg, patients with baseline weight ,59 kg were significantly
more likely to develop .25% decline in eGFR (p=0.002). On the
other hand, the difference in this probability between patients with
baseline weight 59–67 kg and those .67 kg was only marginally
significant (p=0.073, log-rank test). Secondly, one-way ANOVA
Figure 1. Flow diagram of patient selection.
doi:10.1371/journal.pone.0022661.g001
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categories were not significantly different (p=0.206). Sensitivity
analysis after adding the variable ‘‘weight change’’ in Model 3
multivariate analysis (Table 3) showed that adjusted hazard ratio
for weight per 5 kg decrement hardly changed (adjusted HR
1.131; 95% CI, 1.007–1.271; p=0.038). Thirdly, Table 5 shows
the median and interquartile values for the actual falls in eGFR
from the baseline to 24, 48, and 96 weeks. The eGFR decreased
gradually in all categories, except for patients with baseline weight
Table 1. Baseline demographics and laboratory data.
Characteristics
Median (IQR) weight (kg) 63 (57–69)
Median (IQR) BMI (kg/m
2) 21.9 (20.3–23.8)
Male, n (%) 471 (95.2)
Median (IQR) age 38 (33–46)
Median (IQR) eGFR (ml/min/1.73 m
2) 120.9 (104.8–138.2)
Median (IQR) serum creatinine (mg/dl) 0.72 (0.64–0.81)
Median (IQR) CD4 count (/ml) 247 (159–371)
Median (IQR) HIV viral load (log10/ml) 3.73 (1.60–4.81)
HIV viral load ,50 copies/ml, n (%) 162 (32.7)
Antiretroviral therapy naı ¨ve, n (%) 208 (42.0)
Key drugs, n (%)*
PIs 403 (81.4)
Ritonavir-boosted PIs 367 (74.1)
LPV/r 175 (35.4)
ATV/r 131 (26.5)
FPV/r 52 (10.5)
DRV/r 9 (1.8)
FPV 14 (2.8)
ATV 4 (0.8)
NFV 15 (3)
SQV 2 (0.4)
IDV 1 (0.2)
NNRTIs 83 (16.8)
EFV 65 (13.1)
NVP 17 (3.4)
ETR 1 (0.2)
INI
RAL 10 (2.0)
Concurrent use of nephrotoxic drug, n (%) 131 (26.5)
Diabetes mellitus, n (%) 30 (6.1)
Hepatitis B, n (%) 75 (15.2)
Hepatitis C, n (%) 52 (10.5)
Hypertension, n (%) 28 (5.7)
Dyslipidemia, n (%) 40 (8.1)
Smoking, n (%) 240 (48.5)
Median (IQR) weight change (kg) 0.0 (22.0–2.25)
Median (IQR) frequency of eGFR monitoring 16 (9.0–27)
(n=495).
*Two patients did not take any key drugs. Three patients took both PI and
NNRTI.
IQR: interquartile range, BMI: body mass index, eGFR: estimated glomerular
filtration rate, PI: protease inhibitor, LPV/r: lopinavir/ritonavir, ATV: atazanavir,
FPV: fosamprenavir, DRV: darunavir, NFV: nelfinavir, SQV: saquinavir, IDV:
indinavir, NNRTI: non-nucleos(t)ide reverse transcriptase inhibitor, EFV:
efavirenz, NVP: nevirapine, ETR: etravirine, INI: integrase inhibitor, RAL:
raltegravir.
doi:10.1371/journal.pone.0022661.t001
Figure 2. Kaplan-Meier curve showing the time to 25%
reduction in eGFR for the whole cohort. eGFR: estimated
glomerular filtration rate.
doi:10.1371/journal.pone.0022661.g002
Table 2. Univariate analysis for TDF-associated renal
dysfunction.
HR 95%CI P value
Weight per 5 kg decrement 1.23 1.10–1.37 ,0.001
BMI per 1 kg/m
2 decrement 1.14 1.05–1.23 0.001
Male gender 0.54 0.26–1.11 0.094
Age per 10 years 1.22 1.02–1.45 0.027
eGFR per 10 ml/min/1.73 m
2 1.10 1.05–1.15 ,0.001
Serum creatinine .0.8 mg/dl 0.51 0.30–0.88 0.014
CD4 count ,200/ml 1.97 1.32–2.93 0.001
HIV viral load per log10/ml 1.15 1.01–1.30 0.037
Antiretroviral therapy naı ¨ve 0.98 0.63–1.52 0.927
Concurrent key drugs
Any PIs 1.52 0.89–2.59 0.124
Ritonavir boosted PIs 1.46 0.91–2.33 0.116
LPV/r 1.45 0.97–2.17 0.072
ATV/r 1.05 0.66–1.68 0.826
Concurrent nephrotoxic drug 1.59 1.04–2.42 0.031
Diabetes mellitus 1.57 0.76–3.24 0.220
Hepatitis B 1.36 0.82–2.24 0.231
Hepatitis C 1.80 1.07–3.04 0.028
Hypertension 1.18 0.51–2.69 0.702
Dyslipidemia 0.97 0.47–2.00 0.932
Smoking 1.57 1.05–2.36 0.028
TDF: tenofovir, HR: hazard ratio, CI: confidence interval, BMI: body mass index,
eGFR: estimated glomerular filtration rate, PI: protease inhibitor, LPV/r:
lopinavir/ritonavir, ATV: atazanavir.
doi:10.1371/journal.pone.0022661.t002
Small Body Weight and TDF Renal Dysfunction
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22661.67 kg. Fourthly, the number (percentage) of patients whose
eGFR decreased to ,60 ml/min/1.73 m
2 was not different
among the baseline weight categories (p=0.229), whereas the
number of patients who discontinued TDF with a clinical
diagnosis of renal dysfunction due to TDF varied significantly
according to body weight (p=0.001, chi-square test, Table 6).
None of the patients showed reduction of eGFR to ,10 ml/min/
1.73 m
2.
Discussion
In this Japanese cohort, 19.6% of the patients experienced
eGFR decline of more than 25% from the baseline after
commencement of TDF. The incidence of TDF-associated renal
dysfunction was 10.5 per 100 person-years. Multivariate analysis
identified smaller body weight and smaller body mass index as
significant and almost significant factors, respectively, for TDF-
associated renal dysfunction.
The incidence of TDF-associated renal dysfunction in
patients with small body weight might be higher than previously
reported in studies of patients with larger statures. Studies from
North America, Europe, and Australia reported an incidence of
,1% to 4.3% for TDF-related renal dysfunction, although the
definition used for the diagnosis of renal impairment was
different among the studies and varied from an increase in
serum creatinine from .0.5 to .2 mg/dL from baseline [1–
3,5,13]. Several studies conducted in these regions indicated
that the range of patients’ mean body weight was 69–74 kg,
indicating that their patients were heavier than those of the
present study with a median weight of 63 kg [2,6,12,14]. The
impact of the comparatively lower body weight seems stronger
in our patients probably because they do not appear to have
many of the other established risk factors for TDF-associated
renal dysfunction despite the high incidence of 10.5 per 100
person-years. For example, they were comparatively young with
a median age of 38 years, CD4 count was relatively maintained,
a n da p p r o x i m a t e l y3 0 %h a ds u p p r e s s e dH I Vv i r a ll o a da t
baseline (Table 1). Furthermore, they were less likely to have
hypertension, dyslipidemia, and diabetes mellitus.
Table 3. Multivariate analysis to estimate the effect of lower body weight on TDF-associated renal dysfunction.
Model 1 Crude Model 2 Adjusted Model 3 Adjusted
HR 95%CI HR 95%CI HR 95%CI
Weight per 5 kg decrement
" 1.23 1.10–1.37 1.21 1.07–1.36 1.13 1.01–1.27
Male gender 0.88 0.41–1.89 0.57 0.26–1.26
Age per 10 years
" 1.16 0.98–1.38 1.24 1.04–1.49
Serum creatinine .0.8 mg/dl 0.62 0.35–1.07
CD4 count ,200/ml 1.65 0.97–2.79
HIV viral load per log10/ml 1.05 0.90–1.23
Boosted PIs 1.54 0.93–2.54
Concurrent use of nephrotoxic drug 1.23 0.77–1.97
Hepatitis C 1.57 0.92–2.69
Smoking
" 1.65 1.09–2.48
"P,0.05 in Model 3.
TDF: tenofovir, HR: hazard ratio, CI: confidence interval, PI: protease inhibitor.
doi:10.1371/journal.pone.0022661.t003
Table 4. Multivariate analysis to estimate the impact of BMI decrement on TDF-associated renal dysfunction.
Model 1 Crude Model 2 Adjusted Model 3 Adjusted
HR 95%CI HR 95%CI HR 95%CI
BMI per 1 kg/m
2 decrement 1.14 1.05–1.23 1.13 1.05–1.22 1.07 1.00–1.16
Male gender 0.67 0.32–1.38 0.48 0.23–1.03
Age per 10 years
" 1.20 1.01–1.43 1.27 1.06–1.52
Serum creatinine .0.8 mg/dl 0.60 0.35–1.04
CD4 count ,200/ml 1.64 0.97–2.79
HIV viral load per log10/ml 1.05 0.90–1.23
Boosted PIs 1.49 0.90–2.45
Concurrent use of nephrotoxic drugs 1.22 0.76–1.94
Hepatitis C 1.62 0.94–2.76
Smoking
" 1.63 1.08–2.46
"P,0.05 in Model 3.
BMI: body mass index, TDF: tenofovir, HR: hazard ratio, CI: confidence interval, PI: protease inhibitor.
doi:10.1371/journal.pone.0022661.t004
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body weight was significantly associated with TDF-associated
renal dysfunction but not each 1 kg/m
2 decrement in BMI
suggests that weight might be more useful and handy information
to estimate the risk for TDF-associated renal dysfunction than
BMI. Thus, patient’s body weight is an important risk factor to
consider at the time of TDF prescription.
Our study is one of a few that have examined the impact of
TDF-associated renal dysfunction in patients with small body
weight, but is the first to examine the impact of small body weight
as a primary exposure by creating the model used for multivariate
analysis [16–18]. One study from Thailand that included patients
with a median weight of 56.5 kg reported a similar incidence of
16.2 per 100 person-years for developing TDF-associated renal
dysfunction [17]. They concluded that the small body weight of
their patients was probably associated with the high incidence of
TDF-associated renal dysfunction. Our study confirmed that
conclusion and provided statistically-backed evidence that small
body weight is a significant risk factor of TDF-associated renal
dysfunction by using a multivariate model with least multi-
collinearity to evaluate the impact of small body weight. The
results of the present study could be applied to many countries in
Asia and Africa, where stature and body weight of the population
are comparatively smaller.
This study adopted a decrease in eGFR of .25% as a definition
for TDF-associated renal dysfunction. This criterion is one of
common methods in evaluating renal function [22,23]. Using this
definition, however, does not mean that all patients with .25%
fall in eGFR have severe renal dysfunction. However, the
definition of renal dysfunction based on a fall in eGFR of
.25% is probably more sensitive than that based on eGFR
,60 ml/min/1.73 m
2, in patients with comparatively good
baseline renal function, such as patients of our study. Adopting
this definition could be useful in detecting early renal dysfunction
and in the clinical decision making regarding the need for certain
interventions, for example, discontinuation of TDF. Early
detection of renal dysfunction is particularly important in patients
with HIV infection, because kidney disease may be associated with
AIDS and death, and TDF-associated renal dysfunction might be
irreversible [27,28].
Since the calculation of eGFR using the MDRD formula is
based on serum creatinine, age, race and gender, any fall in eGFR
is influenced by hypercreatininemia caused by increased muscle
mass [29]. It is possible that the muscle mass increases in patients
on ART, especially those with low weight at baseline compared to
those with higher weight, reflecting reversal of wasting in those
patients who were most malnourished. Such increase in muscle
mass could then result in a fall in eGFR despite no change in
actual renal elimination of creatinine. However, complementary
analysis showed that weight change throughout the follow-up
period was not significantly different among patients with different
baseline weight, and the sensitivity analysis demonstrated that
weight change did not alter the significance of every 5 kg
decrement.
In the present study, high eGFR and low serum creatinine levels
at baseline were identified as risk factors for falls in eGFR of more
than 25%, in contrast to several previous studies that showed high
serum creatinine and low eGFR were risk factors [4,10,25]. While
the exact reason for this discrepancy is unknown at present, it could
be related to differences in the definition of TDF-associated renal
dysfunction. The aforementioned Thai study used the same
definition applied in the present study and a Canadian study that
used the definition of 1.5-fold increase in serum creatinine from
baseline also reported high eGFR and low serum creatinine level at
baseline as risk factors [17,30]. Thus, it is plausible to observe a fall
in eGFR when the baseline value is high, since Horberg et al.
reported that patients with baselineeGFR of.80 ml/min/1.73 m
2
were likely to show a pronounced fall in eGFR with TDF use [31].
Multivariate analysis also suggested that old age and current
smoking are significant risks for TDF-associated renal dysfunction
Figure 3. Kaplan-Meier curve showing the time to 25%
reduction in eGFR according to baseline weight categories.
Compared to patients with body weight .67 kg, those with weight
,59 kg were more likely to develop .25% decline in eGFR (P=0.002),
whereas those with weight 59–67 kg showed only a marginal
significance (P=0.073, log-rank test). eGFR: estimated glomerular
filtration rate.
doi:10.1371/journal.pone.0022661.g003
Table 5. Median and interquartile range of the actual fall in eGFR from the baseline to 24, 48, and 96 weeks, according to body
weight.
Total (n=495) ,59 kg (n=167) 59–67 kg (n=168) .67 kg (n=160)
fall in eGFR(ml/min/1.73 m
2) fall in eGFR fall in eGFR fall in eGFR
median IQR median IQR median IQR median IQR
to 24 weeks 7.8 (21.7–18.1) 9.8 (23.6–22.6) 6.8 (21.5–17.3) 7.3 (21.8–15.4)
to 48 weeks 9.0 (20.7–21.9) 13.0 (20.2–29.3) 7.2 (21.2–20.0) 8.1 (20.6–18.6)
to 96 weeks 9.3 (20.5–23.1) 13.4 (1.2–33.2) 8.6 (20.2–21.7) 7.5 (22.4–19.8)
eGFR: estimated glomerular filtration rate, IQR: interquartile range.
doi:10.1371/journal.pone.0022661.t005
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have to be interpreted with caution, because these multivariate
analyses were formulated to primarily evaluate weight decrement,
not age or smoking.
The mechanism of TDF-associated renal dysfunction is not fully
understood. TDF-associated renal dysfunction probably develops
as a result of complex interaction of pharmacological, environ-
mental, and genetic factors, rather than small body weight only
[32]. It should be noted, however, that small body weight has been
identified as a risk factor for TDF-associated renal dysfunction not
only in clinical trials, but also in in vitro and pharmacokinetic
studies [33–36]. TDF is the prodrug of acyclic nucleotide analog
tenofovir, which is excreted by both glomerular filtration and
active tubular secretion. In vitro studies showed that tenofovir
exhibits mitochondrial toxicity in renal proximal tubular cells, and
animal studies demonstrated that renal tubular dysfunction was
associated with the dose and plasma drug concentrations of TDF
[34,35]. Furthermore, pharmacokinetic studies showed that small
body weight is associated with reduced plasma TDF clearance and
thus high plasma TDF concentrations, which could result in renal
tubular dysfunction. [33,36].
There are several limitations to our study. First, because of the
retrospective nature of the study, patients with possible risks for
TDF-associated renal dysfunction could have not been prescribed
TDF. Because of this selection bias, the incidence of TDF-
associated renal dysfunction might be underestimated. Second, the
study did not compare the incidence of renal dysfunction in a
control group (TDF-free ART). Due to the small body weight in
Japanese or other factors such as genetics, the use of ART without
TDF might cause higher incidence of renal dysfunction as well.
Third, as discussed above, the definition of TDF-associated renal
dysfunction, especially the criteria used to evaluate proximal renal
tubular damage, is not uniformly established in the field and is
different in the published studies. Accordingly, we decided to
adopt changes in eGFR, instead of parameters for proximal renal
tubular damage. Using the eGFR as a marker for TDF-associated
renal dysfunction, our results might have underestimated the
incidence of TDF-associated renal dysfunction.
In conclusion, the present study demonstrated a high incidence
of TDF-associated renal dysfunction among Japanese patients, a
potentially high-risk group due to the low median body weight.
The results also identified small body weight as a risk for TDF-
associated renal dysfunction in a statistical model that included
small body weight as a primary exposure. TDF is certainly a drug
of choice for one of the components of the first line therapies for
HIV infection. However, the importance of close monitoring for
renal function in patients with small body weight should be
emphasized for early detection of TDF-associated renal dysfunc-
tion.
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